Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116870 · ClinicalTrials.gov registry record · Phase 2
MARS - Monitored Atherosclerosis Regression Study
A Phase 2 study of Coronary Artery Disease and Atherosclerosis, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 2
- Development phase
- 270
- Enrollment target
- 1
- Study location
NCT00116870 is a Phase 2 study of Coronary Artery Disease and Atherosclerosis that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 270 participants, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00116870, a Phase 2 study of Coronary Artery Disease and Atherosclerosis, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 270 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether significant alterations in serum lipoproteins as provided by the drug lovastatin can substantially reduce atherosclerosis progression or even induce regression.
Conditions Studied
Interventions
- DRUG lovastatin
Study Locations (1)
California
- Atherosclerosis Research Unit, Division of Cardiovascular Medicine, Department of Medicine - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 1985-06 |
| Est. Completion | 1992-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00116870
The ClinicalTrials.gov registry entry for NCT00116870 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 270 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (79% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which lovastatin is the first listed.
NCT00116870 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00116870 about?
NCT00116870 is a clinical study titled "MARS - Monitored Atherosclerosis Regression Study". The purpose of this study is to determine whether significant alterations in serum lipoproteins as provided by the drug lovastatin can substantially reduce atherosclerosis progression or even induce regression.
What is the current status of trial NCT00116870?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 270 participants. The study started on 1985-06. Estimated completion is 1992-02.
What conditions does trial NCT00116870 study?
This clinical trial studies the following conditions: Coronary Artery Disease, Atherosclerosis.
What interventions are being tested in trial NCT00116870?
The interventions under investigation include: lovastatin (DRUG).
Who is sponsoring clinical trial NCT00116870?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00116870 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina.
RECRUITING · Phase 2
-
Prevent Cardiac Surgery Associated AKI Trial
RECRUITING · Phase 2
-
Familiarization and Safety Study of PB127 Ultrasound Contrast Agent
COMPLETED · Phase 2
-
High Ticagrelor Loading Dose in STEMI
COMPLETED · Phase 2
-
TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent
COMPLETED · Phase 2
-
Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.